IPO - Azitra, Inc.

Form Type: 424B5

Filing Date: 2025-05-02

Corporate Action: Ipo

Type: New

Accession Number: 000164117225008341

Filing Summary: Azitra, Inc. has filed a prospectus under Rule 424(b)(5) to facilitate a resale offering by Alumni Capital of up to 66,889,632 shares of common stock and up to 6,688,632 shares underlying warrants. The shares are being sold under a Purchase Agreement dated April 24, 2025, which grants Alumni Capital the right to purchase up to $20 million of shares, along with a potential $2.6 million upon exercise of the warrants. The offering details include that the company will not receive proceeds from resale but may receive proceeds from the initial sale of shares. Azitra is positioned within precision dermatology, focusing on genetically engineered microbes for therapeutic applications. The company is currently advancing three key therapeutic candidates through clinical trials, aiming to address various skin conditions. The common stock is listed on the NYSE American under the symbol “AZTR,” and as of April 30, 2025, the share price was reported at $0.323. This prospectus sets forth the offering terms, associated risks, and the company’s strategic vision for growth in the dermatology market, which is anticipated to grow significantly over the coming years.

Form Type: S-1

Filing Date: 2025-04-28

Corporate Action: Ipo

Type: New

Accession Number: 000164117225006507

Filing Summary: Azitra, Inc. is filing a Registration Statement under the Securities Act of 1933 to register up to 66,889,632 shares of common stock and 6,688,632 shares underlying warrants for resale by Alumni Capital LP. The offering is expected to commence as soon as practicable after the registration statement is declared effective. The company, based in Branford, Connecticut, is a clinical biopharmaceutical company focused on precision dermatology, utilizing a proprietary microbial library and advanced technology to develop innovative therapies for skin diseases. They have three lead product candidates, including ATR-12 for Netherton syndrome and ATR-04 for rash related to cancer treatments, and they are engaged in strategic partnerships to enhance product development. The document outlines potential market opportunities, especially in rare skin diseases, and highlights the company's emerging growth status and its implications for regulatory compliance. The company aims to utilize its advanced platforms to create a sustainable pipeline of therapeutics in dermatology, backed by a strong leadership team with extensive experience in biotech.